Guangyu Ma
28 Fuxing Road
Haidian, 100853, China
Haidian, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Pharmacokinetics and Dosimetry of 177Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial.
Journal: Molecular pharmaceutics
Published: June 05, 2026
The efficacy assessment of neoadjuvant TKI and anti-PD-1 combination therapy followed by surgery for hepatocellular carcinoma using PERCIST criteria: an exploratory study.
Journal: European journal of radiology
Published: May 07, 2026
Expression and prognostic impact of CD73 in classical Hodgkin lymphoma.
Journal: Annals of hematology
Published: January 18, 2026
Uptake of 18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors.
Journal: EJNMMI reports
Published: January 07, 2026
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.
Journal: Signal transduction and targeted therapy
Published: June 25, 2025
Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors: a prospective study.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 27, 2025
Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography.
Journal: Molecular pharmaceutics
Published: February 24, 2025
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 20, 2024
Preclinical Study of a Dual-Target Molecular Probe Labeled with 68Ga Targeting SSTR2 and FAP.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 17, 2024
Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
Journal: Annals of hematology
Published: March 25, 2024
Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
Journal: Frontiers in immunology
Published: May 09, 2023
The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
Journal: Frontiers in immunology
Published: January 27, 2023
Last Updated: 09/26/2026